United Therapeutics Corporation
In the published model solve dated 2026-Q2, anchored at $518.86, United Therapeutics Corporation (UTHR) is priced for -1.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
• United Therapeutics is a pulmonary-hypertension specialist whose engine is the Tyvaso franchise; its inhaled dry-powder version, Tyvaso DPI, grew revenue 9% year over year to anchor a portfolio that produces a 45% operating margin. [Source: UTHR Q1 2026 earnings release, May 2026] • The company is debt-free with about $2.15 billion of net cash and roughly 45% operating margins, and it authorized a new $2 billion buyback, but Q1 2026 revenue slipped about 2% as the older nebulized Tyvaso fell 2
Is UTHR overvalued? See what's priced in →
825 institutional managers reported holding UTHR in 13F filings for the quarter ended 2026-03-31. Together they hold about 87% of the company; the top 10 hold 46%. 96 opened new positions that quarter. Held by BlackRock, Vanguard Group, Wellington Management, among others. On the short side, 2.1M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (4.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
UTHR has cut its share count 2.9% over the past five years, spending $3.50B on repurchases. It pays no dividend. Cash returned over the past three years: $3.50B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at UTHR over the trailing three years. Absence is a fact about the company, not a signal. 14 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
UTHR's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-03 | -3.4% | -1.5% |
| 2023-11-02 | +2.4% | +0.8% |
| 2024-02-22 | +1.6% | +8.4% |
| 2024-05-02 | +10.2% | +20.5% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
UTHR's latest 8-K filings: 2026-08-05 (items 2.02, 9.01); 2026-07-23 (items 5.02, 7.01, 9.01); 2026-06-29 (items 5.02, 5.07, 9.01); 2026-05-06 (items 2.02, 9.01); 2026-03-30 (items 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.